Ace inhibitor

The European Commission ( EC ) has approved a new indication for Praluent ( Alirocumab ), to reduce cardiovascular (...


The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in...


The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...



The European Commission ( EC ) has approved Lynparza ( Olaparib ) as a 1st-line maintenance treatment for women with...


Results of a new subgroup analysis from the phase 3 CREDENCE study, showing Canagliflozin ( Invokana ) has significantly reduced...


People who have been prescribed statins to lower their cholesterol levels sometimes complain of muscle aches and pains and therefore...


The results of a study has shown that patients living with HIV and one of a variety of potentially deadly...


Patients with left-sided heart failure who get implanted devices to improve the pumping of their hearts may be more likely...


The results from the global phase III PARAGON-HF study, investigating the safety and efficacy of Sacubitril / Valsartan ( Entresto...


The FDA ( U.S. Food and Drug Administration ) has approved Biktarvy ( Bictegravir 50mg / Emtricitabine 200mg / Tenofovir...


ECLIPSE trial has demonstrated that Guselkumab ( Tremfya ) was superior to Secukinumab ( Cosentyx ) in treating adults with...


Dulaglutide ( Trulicity ) significantly improves A1C ( average blood sugar concentration over two to three months ) when added...


The European Commission has granted marketing authorisation for Lokelma ( formerly ZS-9, sodium Zirconium cyclosilicate ) for the treatment of...


The European Medicines Agency ( EMA ) has approved Lynparza ( Olaparib ) tablets ( 300mg twice daily ) for...


HER2 targeted therapies have substantially improved the prognosis of patients with breast cancer however they can be associated with cardiac...


Guidelines strongly recommend patients with heart failure with reduced ejection fraction ( HFrEF ) be treated with multiple medications proven...


Updated preliminary clinical data from an ongoing phase I dose escalation and expansion study evaluating the safety and efficacy of...


Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich ( Germany...


Results of the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met...